Together, these studies findings implicate defective expression and function of PPAR-γ in SSc, and raise the possibility that activating PPAR-γ using ligand agonists such as the thiazolidenediones, novel non-agonist ligands, or the triterpenoid CDDO, might be novel therapeutic approaches. The gene discussed is PPARG; the disease is systemic sclerosis.